BAX and liver cancer: CRPBT can significantly down-regulate the phosphorylation of PI3K and AKT in liver cancer cells, up-regulate the Bax/Bcl-2 ratio, and inhibit the expression of MMP2/3, N-cadherin and Vimetin proteins.